| Pioglitazone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Pioglitazone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Pioglitazone | hsa00600 | Sphingolipid metabolism | 2.68E-02 | 2 | P07602, Q13510 | PSAP, ASAH1 | More | |
| Pioglitazone | hsa00830 | Retinol metabolism | 4.55E-02 | 1 | P00325 | ADH1B | More | |
| Pioglitazone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Pioglitazone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Pioglitazone | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | |
| Pioglitazone | hsa04071 | Sphingolipid signaling pathway | 1.79E-02 | 3 | Q13510, Q13362, Q9UQC2 | ASAH1, PPP2R5C, GAB2 | More | |
| Pioglitazone | hsa04072 | Phospholipase D signaling pathway | 4.37E-02 | 3 | Q9UQC2, Q8WYR1, Q08828 | GAB2, PIK3R5, ADCY1 | More | |
| Pioglitazone | hsa04151 | PI3K-Akt signaling pathway | 3.25E-02 | 5 | O43521, Q13362, Q8WYR1, P23458, Q6ZUJ8 | BCL2L11, PPP2R5C, PIK3R5, JAK1, PIK3AP1 | More | |
| Pioglitazone | hsa04213 | Longevity regulating pathway - multiple species | 8.24E-03 | 2 | Q08828, P0DMV8 | ADCY1, HSPA1A | More | |
| Pioglitazone | hsa04270 | Vascular smooth muscle contraction | 2.68E-02 | 3 | Q08828, P35579, P35318 | ADCY1, MYH9, ADM | More | |
| Pioglitazone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Pioglitazone | hsa04611 | Platelet activation | 1.42E-02 | 3 | Q9Y490, Q08828, Q8WYR1 | TLN1, ADCY1, PIK3R5 | More | |
| Pioglitazone | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Pioglitazone | hsa04621 | NOD-like receptor signaling pathway | 3.19E-02 | 3 | P23458, Q9H3M7, P43490 | JAK1, TXNIP, PBEF1 | More | |
| Pioglitazone | hsa04664 | Fc epsilon RI signaling pathway | 4.73E-02 | 2 | Q9UQC2, P20292 | GAB2, ALOX5AP | More | |
| Pioglitazone | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | |
| Pioglitazone | hsa04915 | Estrogen signaling pathway | 1.02E-02 | 3 | Q08828, P0DMV8, Q15788 | ADCY1, HSPA1A, NCOA1 | More | |
| Pioglitazone | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | |
| Pioglitazone | hsa04921 | Oxytocin signaling pathway | 3.76E-02 | 3 | Q08828, Q96RR4, Q8WYR1 | ADCY1, CAMKK2, PIK3R5 | More | |
| Pioglitazone | hsa04972 | Pancreatic secretion | 4.73E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
| Pioglitazone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Pioglitazone | hsa05145 | Toxoplasmosis | 6.86E-03 | 3 | P23458, Q8WYR1, P0DMV8 | JAK1, PIK3R5, HSPA1A | More | |
| Pioglitazone | hsa05162 | Measles | 2.68E-02 | 2 | P23458, P0DMV8 | JAK1, HSPA1A | More | |
| Pioglitazone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Pioglitazone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Pioglitazone | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
